Published in Blood Weekly, September 28th, 2006
This is the result of an intensive internal screening study designed to recognize promising candidates, and ultimately identify a lead candidate for further preclinical and clinical development.
The coating product, identified as KBI-4258, builds upon Kane Biotech's proprietary dispersinB technology. DispersinB is a novel enzyme responsible for inhibition and dispersal of bacterial biofilms,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.